Changes in ocular signs and symptoms in patients switching from bimatoprost-timolol to tafluprost-timolol eye drops: an open-label phase IV study.

ABSTRACT:

Objectives

Bimatoprost-timolol (bimatoprost 0.03%-timolol 0.5% fixed-dose combination [FDC]) and tafluprost-timolol (tafluprost 0.0015%-timolol 0.5% FDC) eye drops are currently the only topical intraocular pressure (IOP)-reducing therapies available as preservative-free (PF) prostaglandin and timolol FDC. The aim of this study was to investigate changes to ocular signs and symptoms when patients with ocular hypertension (OH) or open-angle glaucoma (OAG) switched from PF or benzalkonium chloride (BAK)-preserved bimatoprost-timolol to PF tafluprost-timolol eye drops.

Design

This was a 12-week, open-label, phase IV study.

Setting

Sixteen centres in Finland, Germany, Italy and the UK.

Participants

Patients with OH or OAG (IOP on medication ≤21 mm Hg), treated with

SUBMITTER: Bourne RRA 

PROVIDER: S-EPMC6500185 | biostudies-literature | 2019 Apr

REPOSITORIES: biostudies-literature